Immune checkpoint inhibitors, especially those targeting the programmed cell death protein 1 (PD-1) and its ligand programmed death-ligand 1(PD-L1), have exhibited notable clinical efficacy in HCC, highlighting their potential therapeutic value in this malignancy [7,8]. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.